FDA
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform Rating on Structure Therapeutics (GPCR)
-
-
-
-
-
-
-
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
-
-
-
323,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

